Eli Lilly Cut Insulin 70% and Got Richer. The Charity Was the Strategy.

On March 1, 2023, Eli Lilly cut the list price of Humalog from $274.70 a vial to $66.40 — a 70% reduction on the insulin millions of Americans depend on — and capped patient out-of-pocket costs at $35 a month.⁴ The press read it as a moral awakening. The diabetes community read it as relief. Wall Street read it correctly: as a trade. Within a year, Lilly's U.S. revenue would be up 39%, and its realized prices up 27%.⁶ A company does not give up its flagship product's price and grow faster unless the price it gave up was the wrong place to be standing.

The official story is that Eli Lilly listened to its conscience and did the right thing. The truer story is that it stopped defending a position it was about to lose anyway — and converted the loss into a reputational asset it is now spending on something far more valuable. The insulin cut wasn't generosity. It was a managed retreat from a battlefield the company had already decided to abandon.

How insulin got expensive in the first place

Lilly didn't price insulin high because the molecule got better. Its own internal documents, reviewed by the Senate Finance Committee, show the Humalog KwikPen's wholesale list price climbing from $323 in 2013 to $530 in 2017 — a 64% jump in four years on a product whose chemistry barely changed.¹ The Committee, working through more than 100,000 pages of company records, found something stranger still: Lilly, Sanofi, and Novo Nordisk raised their list prices in lockstep — a practice it called 'shadow pricing' — sometimes within hours of each other, without meaningful improvements in the drugs.² List price had detached from the medicine entirely. It had become a lever in a hidden negotiation.

Here is the mechanism that the outrage obscured. By 2022, pharmacy benefit managers — the middlemen who decide which drugs insurers cover — were extracting enormous rebates as the price of formulary access. The higher the list price, the bigger the rebate a manufacturer could offer back. So list prices inflated upward as a kind of theater: a sticker number designed to be discounted, while the net price insurers actually paid stayed far lower.⁸ The patient without insurance — the one paying cash — got crushed by a number that was never meant for them. The system had built a price that hurt the most vulnerable people precisely because they were outside the negotiation it was designed for.

Why the cut cost less than it looked

This is the part the headline buries. Because the pre-cut list price had been inflated far above the net price insurers actually paid, cutting the list number 70% did not cut Lilly's real-world revenue by anything close to 70%. USC Schaeffer researchers said it plainly: even after the reduction, Lilly was still making a profit, and the impact on payers was much narrower than the headline implied because so many insured patients never paid list price in the first place.⁸ Lilly gave up a number that was already mostly fictional. The publicity it bought with that fiction was entirely real.

Now stack up the pressures Lilly faced standing still. The Senate Finance Committee had already published its findings and subpoenaed Lilly's records, a fact the company disclosed in its own 10-K.³ The Inflation Reduction Act had capped insulin at $35 a month — but only for Medicare Part D enrollees, leaving the commercial market exposed and the question of who would extend the benefit hanging in the air. Generic and low-cost rivals were circling. And in November 2022, a fake verified Twitter account — empowered by the new $8 blue-check program — tweeted that Lilly's insulin was free, and the stock fell roughly 4.37%, with an estimated $15 billion in market value erased in the panic.⁵ No single one of these forced the cut. Together they made defending the old price more expensive than abandoning it.

Where the money actually went

Watch what happened to the revenue mix the moment the cut took effect. In Q4 2023, Lilly's U.S. revenue jumped 39% to $6.46 billion — and the engine was not insulin. It was a 27% increase in realized prices driven primarily by Mounjaro, the company's new incretin blockbuster, even as Humalog and the older Trulicity saw lower realized prices.⁶ The pattern is unmistakable: Lilly let the price fall on the mature, embattled product and let it rise on the new, defensible one. The insulin cut and the Mounjaro premium are not two separate stories. They are one pivot, seen from both ends.

The brand narrative that the insulin cut purchased — Lilly as the drugmaker that finally did right by patients — is exactly the cover a company wants when it is about to charge premium prices on a class of obesity and diabetes drugs the entire world suddenly wants. Full-year 2024 revenue landed near $45 billion, 32% growth, and the 2025 guidance sits at $58 to $61 billion, growth the company attributes overwhelmingly to Mounjaro and Zepbound volume.⁷ You can charge more for the new thing when the public has just decided you are the company that lowered the price of the essential thing. The moral high ground, bought cheaply on insulin, anchors the pricing power on everything that comes next.

Wasn't it just the tweet — or just decency?

The fair objection runs two ways. The cynical version says a fake tweet and a $15 billion scare panicked Lilly into a cut. The generous version says the company simply did the right thing. Both are too tidy. The tweet was an accelerant, not a cause — it sharpened a reputational cost that the Senate investigation, the competitors, and the Medicare cap had already been building for two years.⁵³ And the decency reading fails the evidence test: a genuinely sacrificial move would have dented the bottom line, yet revenue and realized prices climbed right through it.⁶ The most honest read is the least flattering and the most strategic. Lilly faced a price it could no longer hold and a future it wanted to price aggressively, and it solved both problems with a single, well-timed gesture. That it also helped real patients is true — and beside the point of why it happened when it did.

Eli Lilly's pricing strategy didn't soften. It relocated. The company spent a fictional list price and a manufactured scare to buy something it could not have purchased with an ad campaign at any cost: the reputation of the drugmaker that made medicine affordable. Then it walked that reputation across the room and set it down next to the most lucrative drugs in its history. The 70% cut was never a discount. It was a down payment on the right to charge a premium — and the world, grateful, keeps writing the rest of the check.